Mohammad AskarPublic working copy · medical review pending

Coats, MacTel and phakomatoses · 217

Coats disease, macular telangiectasia and phakomatoses: stages, signs and systemic responsibility

A complete teaching draft built on the second original lecture: the Shields stage table, the Coats versus retinoblastoma comparison, the neurofibromatosis comparison of NF1 and NF2, the examination dashboard and all original numbers are kept. Areas where the original wording needs clinical qualification are marked.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Coats disease is a sporadic, non-hereditary exudative retinal telangiectasia, mostly unilateral, and retinoblastoma must be excluded urgently in any child with leukocoria. The Shields stages and their treatment options describe a range of individual decisions, not a fixed operation list. Macular telangiectasia type 2 is a bilateral neurodegenerative disease; anti-VEGF is for a neovascular complication, not for the cavities. Ocular phakomatosis signs start syndrome-specific surveillance, and the ENCELTO evidence is structural, not a restoration of vision.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01From vascular pathology to a management strategy

This lecture asks for a core competence in specialised ophthalmic training: distinguishing isolated ocular malformations from multisystem disease. The clinical difficulty is that several of these diseases first become visible at the fundus, while their consequences reach far beyond the eye. Some of them threaten vision, and some are associated with tumours that can be life-threatening, so the topic belongs to everyday practice and to the specialist examination. 1

The original sets four learning objectives. The first is safe use of the Shields classification to decide treatment in Coats disease. The second is a reliable differentiation between the exudative process of Coats disease and the solid tumour of retinoblastoma; the original calls this pathognomonic differentiation, and that word is qualified here because no single sign is pathognomonic. The third is an understanding of macular telangiectasia type 2 as a primarily neurodegenerative disease, including the cell-based implant. The fourth is systematic recording of the ocular phenotypes of the phakomatoses so that interdisciplinary screening can begin. 1

Coats disease is the bridge from pure vascular pathology to clinical management strategy. It shows how a vascular malformation becomes an exudative retinal problem, how the stage changes the treatment, and why a tumour must always be excluded first. The same logic then returns in the phakomatoses, where a retinal finding is the visible part of a systemic disease. 1

02Coats disease: epidemiology, genetics and the exudative cascade

Coats disease is described in the original as an idiopathic, mostly unilateral disease with telangiectatic and aneurysmal retinal vessels. The resulting disturbance of the blood–retina barrier produces massive lipid-containing, xanthochromic exudates. The clinical spectrum therefore runs from local vascular changes to a total exudative retinal detachment. 1

The original epidemiology is 95 % unilateral disease, a male-to-female ratio of 3:1, and a typical manifestation age below 8 years. These are population descriptions. They were not re-verified against a primary cohort in this review, and they must never be used to decide that one child's bilateral or atypical findings are not a tumour. 1

The original calls the disease primarily non-hereditary but adds that instability on chromosomes 3 and 13 has been demonstrated in research approaches. That sentence is recorded here as an unresolved original claim. No primary source was inspected for it, the mechanism is not established, and it is neither a diagnostic criterion nor evidence that Coats disease is inherited. 1

The mechanism in the lecture is a sequence: telangiectasias and microaneurysms, preferentially temporal and peripheral, cause exudation; the exudation accumulates as subretinal fluid; and the fluid can progress to a total retinal detachment. This cascade explains why treatment targets leaking vessels and why a large detachment also becomes a drainage problem. 1

One primary retrospective clinical series reported150 patients/158 eyes, median age5 years(range1 month–63 years),114male(76%) and142unilateral(95%). Its referral population and broad age range limit generalisation; it does not establish the original male proportion or a strict childhood age boundary for every setting. 1 5

03The Shields table stage by stage

The Shields table in this lecture pairs each stage with a clinical feature and a therapeutic strategy. It is a decision aid, not a protocol. The stage describes the anatomical situation, while the activity of the exudation, the foveal involvement, the intraocular pressure and the state of the media determine what is done at that stage. 1

Stage 1 describes retinal telangiectasias only. The original strategy is close observation in order to catch the beginning of progression. That is sound only with a defined review interval and a clear trigger for treatment; observation is not the same as discharging the child. 1

Stage 2a describes extrafoveal exudation. The original strategy is targeted laser coagulation or cryotherapy of the leaking areas. Both aim to close abnormal vessels while sparing the fovea, and the choice depends on the location, the media and the child's cooperation under anaesthesia. 1

Stage 2b describes foveal exudation. The original combines laser or cryotherapy with intravitreal medication, using steroids or anti-VEGF agents to reduce macular oedema. Exudation at the fovea is a vision-threatening situation and needs timely treatment; the injection is an adjunct to closing the leaking vessels, not a replacement for it. 1

Stage 3a1 describes a partial detachment without foveal involvement. The original recommends aggressive laser coagulation and notes that cryotherapy is often limited. Aggressive in this context means sufficient coverage of the leaking area, not a higher-risk protocol. Cryotherapy is limited because subretinal fluid insulates the vascular malformations from the cold, an explanation the lecture develops below. 1

Stage 3a2 describes a partial detachment that involves the fovea. The original suggests combination treatment and, where needed, surgical relief. This is the stage at which the visual prognosis becomes more uncertain and the balance between reattachment, vessel closure and surgical risk has to be discussed with the family. 1

Stage 3b describes a total exudative detachment. The original states that external drainage is required so that the retina can lie flat enough for laser. In practice drainage, laser, cryotherapy and anti-VEGF are combined according to the individual eye. None of these measures is a guaranteed cure, and anti-VEGF in particular does not remove the need for vessel closure or for later surgery. 1

Stage 4 describes a total detachment with secondary glaucoma. The original calls the prognosis often poor and gives pain control and intraocular pressure management as the primary aims. That is a realistic description of a severely damaged eye, and it should be discussed openly rather than presented as a routine treatment pathway. 1

Stage 5 is the end stage. The original names phthisis bulbi and permits enucleation only for persistent pain or suspected tumour. Two qualifications are needed. First, stage 5 is not invariably phthisis; an advanced end-stage eye may be shrunken and disorganised, but the course varies. Second, a suspicion of tumour is not a reason to remove an eye without a tumour work-up; it is a reason to obtain one urgently. 1

The original examination tip is that cryotherapy is often less effective from stage 3 onwards because the subretinal fluid isolates the vascular malformations and prevents cold from reaching them. That is a plausible physical explanation and remains useful for understanding the treatment logic. It is not an absolute rule, and the actual choice still depends on the individual eye and the available expertise. 1

The Shields table stage by stage
StageClinical featuresTherapeutic strategy (original and qualification)
Stage 1Only retinal telangiectasias.Close observation to catch the start of progression; define the follow-up interval.
Stage 2aExtra-foveal exudation.Targeted laser coagulation or cryotherapy of the leaks; individual choice.
Stage 2bFoveal exudation.Laser or cryotherapy plus intravitreal medication (steroids or anti-VEGF) to reduce macular oedema.
Stage 3a1Partial detachment without foveal involvement.Original: aggressive laser coagulation; cryotherapy often limited (see below). Sufficient coverage, not a higher-risk protocol.
Stage 3a2Partial detachment with foveal involvement.Combination treatment, possibly surgical relief; individual decision.
Stage 3bTotal exudative detachment.External drainage may be required so that the retina can lie flat for laser; combined with laser, cryotherapy or anti-VEGF as needed.
Stage 4Total detachment plus secondary glaucoma.Often poor prognosis; primary pain control and intraocular pressure management.
Stage 5Phthisis bulbi (end stage).Enucleation only for persistent pain or suspected tumour; stage 5 is not invariably phthisis.

04The comparison table with retinoblastoma, read correctly

The comparison table contrasts Coats disease and retinoblastoma in four rows: the colour of leukocoria, the vessel morphology, the imaging findings and the symmetry. The table is useful for orientation, but it is not a diagnostic algorithm. In a child with a white pupil, the process comes first: examination under anaesthesia, fundus assessment, imaging and a tumour team. 1

In the colour row the original gives xanthochromic, yellowish-white leukocoria for Coats disease and chalky white to pink-creamy leukocoria for retinoblastoma. Colour is a soft clue. A retinoblastoma can look yellowish, and a dense Coats exudate can look chalky, so the colour can neither exclude nor confirm a tumour. 1

The original calls double circulation pathognomonic for retinoblastoma. This is not a validated RB-specific rule: the term describes tumour and retinal vascular circulations and is classically discussed in other intraocular tumours. Neither its presence nor absence establishes or excludes retinoblastoma. Keep the original term pending an exact primary-source clarification and use specialist multimodal assessment. 1

In the imaging row the original states no calcification in Coats disease and calcification in retinoblastoma, called pathognomonic in computed tomography and ultrasound. The correction is that calcification is characteristic and supportive, not pathognomonic, and that its absence does not exclude retinoblastoma. Ultrasound can demonstrate calcification without radiation, while magnetic resonance imaging is used for soft-tissue and optic nerve extent; the two examinations answer different questions. 1

In the symmetry row the original calls Coats disease almost always unilateral and retinoblastoma often bilateral in germline mutation. This is broadly useful, but unilateral retinoblastoma exists, and bilateral disease is not the only presentation of a germline mutation. The practical consequence is unchanged: any child with leukocoria needs a tumour assessment before an exudative diagnosis is accepted. 1

The comparison table with retinoblastoma, read correctly
FeatureCoats diseaseRetinoblastoma
Leukocoria colourXanthochromic, yellowish-white; soft clue only.Chalky white to pink-creamy; colour cannot exclude or confirm.
Vessel morphologyTelangiectasias and aneurysms.Original double circulation; RB-specific diagnostic value unverified
ImagingNo calcification; absence does not exclude retinoblastoma.Calcification is characteristic in computed tomography and ultrasound but not pathognomonic; ultrasound shows calcium, magnetic resonance imaging shows extent.
SymmetryAlmost always unilateral.Often bilateral in germline mutation; unilateral disease exists.

05Laser, drainage and injections as individual tools

The original laser description specifies long duration and low energy, with the aim of a purely thermal effect that obliterates vessels without a rupture risk. This is a technique preference that many surgeons share, not a universal parameter set. Power, duration, spot size and the number of sessions are adapted to the lesion, the media and the response. 1

For massive subretinal fluid the original describes external drainage through a 25G or 27G trocar and calls an infusion line in the anterior chamber strategically essential to keep the intraocular pressure stable during drainage. This review did not verify the technique, its outcomes or its superiority over other approaches. It is retained as an original surgical description, not as a universal recipe; such surgery carries risks of its own and requires an experienced paediatric vitreoretinal team. 1

Intravitreal anti-VEGF agents or steroids are given as an adjunct to reduce exudation. In children the original demands strict monitoring for cataract and glaucoma. Two further points matter for consent and follow-up: the injection does not close the abnormal vessels permanently, and anti-VEGF treatment can be followed by traction or fibrosis. It is therefore an addition to a plan, not a stand-alone cure. 1

The treatment plan continues after the operating room. Exudation, subretinal fluid, laser coverage, intraocular pressure, lens changes and amblyopia all need review. Amblyopia treatment is part of the visual result, because a quiet-looking retina in a child who does not use the eye can still end in poor vision. 1

06Macular telangiectasia: distinguish vascular and neurodegenerative types

The neurodegenerative model applies mainly to type 2, whereas type 1 is predominantly vascular. Use OCT and selected fluorescein angiography to define the pattern; the available modalities and clinical question determine the sequence. 1

Type 1 is unilateral and manifests in younger patients. The original describes a vascular-exudative pathogenesis, similar to a localised Coats variant. It is therefore predominantly a vascular disease with aneurysms and exudation, and it should not be confused with the bilateral neurodegenerative type 2. 1

Type 2 is the most common form, bilateral, idiopathic and neurodegenerative, with manifestation in the 5th to 7th decade. The original lists crystalline deposits, foveal atrophy and cystic cavitations without true oedema. That last phrase is the key: the cavities are structural, not exudative fluid, which is why they do not respond to an injection in the way a macular oedema would. 1

Type 3 is rare, bilateral and occlusive, with capillary loss in the fovea. It is best regarded as a rare and largely historical classification within the spectrum. The label should not be used for every atypical vascular appearance of the macula, and it does not carry the treatment implications of type 2. 1

The original examination tip says that intravitreal anti-VEGF treatment is generally ineffective in type 2 disease unless a secondary choroidal neovascularisation is present. The qualified version is that anti-VEGF has no target in the neurodegenerative cavities, while a neovascular membrane is a treatable complication. The distinction determines whether an injection is rational or merely exposes the patient to risk. 1

Diagnosis and monitoring rely on optical coherence tomography and, where needed, fluorescein angiography. The practical task is to recognise the structural phenotype, to look actively for a neovascular membrane and to avoid treating atrophy as if it were oedema. Vision may continue to decline from the neurodegenerative process even when the macula looks dry. 1

07The implant: corrected names, trial data and structural endpoint

The original presents the NT-501 implant, named Renexus or Densalt, as the current research focus with Food and Drug Administration approval expected in 03/2025. That expected date is obsolete and the naming needs correction. The approved product is ENCELTO (revakinagene taroretcel-lwey), approved in the United States on 5 March 2025 for adult patients with idiopathic macular telangiectasia type 2. NT-501 is a development alias rather than an established generic name, and Renexus or Densalt are historical names from the original material. The implant is an encapsulated cell therapy in which modified cells continuously release ciliary neurotrophic factor (CNTF) with the aim of supporting photoreceptor survival. That is a neuroprotective rationale, and the endpoint reported below measures structure rather than a guaranteed visual gain. No German or European approval is claimed. 2 3

Two sham-controlled, multicentre randomised trials support the approval. The first randomised 120 participants and analysed 115 for efficacy, 58 treated and 57 sham. The second randomised 119 and analysed 113 for efficacy, 59 treated and 54 sham. Eligible eyes had ellipsoid zone loss between 0.16 and 2.0 mm² and visual acuity of at least 54 letters, equivalent to 20/80, and eyes with neovascular macular telangiectasia were excluded. Those criteria define who the evidence describes. 2 3

The primary endpoint was the 24-month rate of ellipsoid zone area loss. In the first trial the rate was 0.075 mm² with treatment versus 0.166 mm² with sham, a difference of −0.091 mm² (95 % confidence interval −0.13 to −0.06), p<.0001. In the second trial the rate was 0.111 mm² versus 0.160 mm², a difference of −0.049 mm² (95 % confidence interval −0.089 to −0.008), p.0186. This is a rate over 24 months, not an absolute 24-month change, and no annualised figure is derived here. 2 3

Microperimetry sensitivity loss differed by −17.75 dB (95 % confidence interval −32.58 to −2.91, p.02; 7 and 4 missing values) in one trial and by −1.95 dB (95 % confidence interval −20.33 to 16.43, p.83; 7 and 6 missing values) in the other. The functional signal is therefore inconsistent. Structural slowing is not visual restoration, missing data matter, the participants were selected adults, and there was no head-to-head comparison with anti-VEGF treatment. 2 3

Pooled safety data include 117 treated and 111 sham participants. Delayed dark adaptation occurred in 27 treated participants (23.1 %) versus 1 sham participant (1 %), and suture-related complications in 18 (15.4 %) versus 3 (2.7 %). The treatment is surgical and needs specialised follow-up. No full operative instruction, figure appraisal or complete label review is claimed here, and the benefit should be described to patients as a structural effect of uncertain functional meaning. 2 3

08Neurofibromatosis and tuberous sclerosis in the comparison tables

The phakomatoses are multisystem hamartosis syndromes, and the ophthalmologist plays a decisive role in early diagnosis. The lecture's comparison tables are a memory aid for the specialist examination, not a substitute for diagnostic criteria. Their value is that they separate two diseases that are easily confused and that they point to the next examination. 1

Neurofibromatosis type 1 is linked to chromosome 17 and a defect in the neurofibromin gene. The original table names Lisch nodules, described as melanocytic hamartomas, as the iris finding, no specific cataract as the lens finding, an optic glioma with fusiform thickening as the imaging finding, and café-au-lait macules with neurofibromas as systemic signs. The Lisch nodule prevalence rises with age but is not 100 % at a defined age, and the nodules are visually neutral. 1 4

Neurofibromatosis type 2 is linked to chromosome 22 and a defect in the merlin gene. The original table names no Lisch nodules, a posterior subcapsular cataract, a meningioma of the optic nerve sheath described as Schienenzustand, and bilateral vestibular schwannomas. Bilateral vestibular schwannomas are the classic core of the disease, but the original word pathognomonic is qualified. The current nomenclature of NF2-related schwannomatosis is noted as pending official verification, so the term NF2 is retained. 1

Schienenzustand is retained as an unresolved original term. It describes an imaging appearance associated with an optic nerve sheath meningioma, but the sign is not pathognomonic, and other optic nerve lesions can produce a similar picture. The term is not replaced here because no authoritative source for the expression was inspected. 1

Tuberous sclerosis (Bourneville-Pringle disease) is presented with three retinal astrocytic hamartoma morphologies: flat and transparent, multinodular and calcified with a mulberry appearance, and mixed forms. All three are retained. The lesions usually do not impair vision, and the calcified mulberry type, although classic, is not the only presentation. Facial angiofibromas, historically called adenoma sebaceum, are the dermatological counterpart named in the lecture. 1

The systemic description must not be turned into a universal triad. Tuberous sclerosis is a multisystem diagnosis with variable skin, neurological, renal and other findings. A retinal astrocytic hamartoma can be an early clue, but it is often asymptomatic and never establishes the diagnosis alone. The correct response is a syndrome assessment with the appropriate specialists. 1

Neurofibromatosis and tuberous sclerosis in the comparison tables
FeatureNF1 (von Recklinghausen)NF2
GeneticsChromosome 17.Chromosome 22.
Iris findingLisch nodules (melanocytic hamartomas); prevalence rises with age.No Lisch nodules.
Lens findingNo specific cataract.Posterior subcapsular cataract.
Optic imagingOptic glioma (fusiform thickening).Optic nerve sheath meningioma (Schienenzustand; term unresolved and not pathognomonic).
SystemicCafé-au-lait macules, neurofibromas.Bilateral vestibular schwannomas.

09Sturge-Weber, von Hippel-Lindau and ataxia-telangiectasia in practice

In Sturge-Weber syndrome the original gives a glaucoma risk of 30 % to 70 %. The mechanisms named are an increased episcleral venous pressure or angle anomalies. Both can coexist, and the risk is context dependent: the age of the patient, the extent of the facial vascular malformation and the angle anatomy all matter. The fundus finding is a diffuse choroidal hemangioma that produces the tomato-ketchup appearance. 1

The original glaucoma section says that surgery with goniotomy or trabeculotomy is often primary because conservative treatment frequently fails in the presence of episcleral venous pressure. This is qualified: many of these eyes do need surgery, but not every patient needs a primary operation, and goniotomy is not feasible or appropriate in every angle. The decision is individual, and lifelong pressure monitoring is retained. 1

Von Hippel-Lindau disease is linked to chromosome 3. The ocular lesion is a retinal capillary hemangioblastoma, described as exophytic and reddish with tortuous feeding and draining vessels. The systemic priority in the lecture is screening for renal cell carcinoma and pheochromocytoma, and the original notes that the eye is often the first manifestation. That statement is clinically plausible teaching, not a measured outcome in this review. 1

The screening statement is an annual fundoscopy from childhood, with regular renal imaging and specialist lifetime care. It is retained as the original recommendation, not as a verified current protocol, because surveillance intervals are age-, organ- and risk-dependent. Small retinal hemangiomas are treated with laser photocoagulation using long duration and low energy, and photodynamic therapy can be added for persistent exudation. Both are individual decisions. 1

Ataxia-telangiectasia is the only autosomal recessive disease in this group. It is caused by biallelic variants in the ATM gene on chromosome 11, and the original triad is ataxia, immunodeficiency and conjunctival telangiectasias, with manifestation between the 5th and 8th year of life. The statement about being the only recessive phakomatosis refers to this teaching group, not to all known neurocutaneous syndromes. 1

The original laboratory section gives raised alpha-fetoprotein and CA-125 and diagnostic confirmation by Western blot showing absence of the ATM protein. Alpha-fetoprotein is often raised and is a classic marker, but it is not always raised, especially in young children. CA-125 is not an established universal diagnostic test. Western blot can support the diagnosis but is not the only confirmation, because genetic testing is central. A normal single test must therefore not be read as exclusion. 1

The guideline section, attributed in the original to DOG and BVA, adds four practical points. Ultra-widefield angiography is described as the gold standard for peripheral non-perfusion in Coats disease, with the original caveat about availability. Neurofibromatosis follow-up aims at early detection of optic glioma, especially when vision drops or colour appears desaturated. Retinal hemangiomas are treated with laser, with photodynamic therapy for exudation. Sturge-Weber glaucoma is often managed surgically. Each point is a recommendation to adapt, not a rule that overrides the individual examination. 1

Sturge-Weber, von Hippel-Lindau and ataxia-telangiectasia in practice
TopicCore concept (lecture)Leading sign or high-yield pointGuidelines and pitfalls
Coats diseaseVascular exudationUnilateral, telangiectasiasHigh yield: differential diagnosis retinoblastoma (calcium?); chromosome 3/13 (original, untraced).
MacTel type 2NeurodegenerationBilateral, foveal atrophyHigh yield: anti-VEGF only for CNV.
NF1HamartosisLisch nodules, fusiform gliomaRegular optic checks.
NF2Schwannoma focusBilateral vestibular schwannomasSchienenzustand sign (meningioma); term unresolved.
Sturge-WeberAngiomatosisTomato-ketchup fundusAssess glaucoma risk up to 70 %.
VHLAngioblastomasCapillary hemangiomasHigh yield: check kidney and adrenal gland.
Louis-BarImmunodeficiencyConjunctival telangiectasiasAFP supports assessment; CA-125 unestablished; ATM protein/genetics need specialist interpretation
What are the main learning points?

Coats disease is a sporadic, non-hereditary exudative retinal telangiectasia, mostly unilateral, and retinoblastoma must be excluded urgently in any child with leukocoria. The Shields stages and their treatment options describe a range of individual decisions, not a fixed operation list. Macular telangiectasia type 2 is a bilateral neurodegenerative disease; anti-VEGF is for a neovascular complication, not for the cavities. Ocular phakomatosis signs start syndrome-specific surveillance, and the ENCELTO evidence is structural, not a restoration of vision.

When is assessment urgent?

A white or yellow pupil, a new squint or unexplained visual loss in a child requires urgent assessment to exclude retinoblastoma. Sudden visual loss, severe pain, marked inflammation, a rise in eye pressure, or suspected infection or neurological disease also require prompt care.

References and access status

  1. 1
    Immutable original export; own Coats, macular telangiectasia and phakomatoses lecture; examiner voice and recording unchecked

    Complete export read; original attribution and any recording, transcript or appointment not independently verified.

  2. 2
    FDA ENCELTO product approval overview; selected extract supplied by the parent reviewer

    Parent-supplied selected official overview extract; the parent reviewer inspected the page on 17 November 2026. The delegate did not access the page, and the full page, review documents and label were not appraised. United States approval only; no German or European claim.

  3. 3
    FDA ENCELTO package insert, selected printed pages 10–15, supplied by the parent reviewer

    Selected printed pages 10 to 15 supplied by the parent reviewer from the official package insert on 17 November 2026. Full instruction for use, operative details, figures and remaining pages were not appraised; no full label read is claimed.

  4. 4
    GeneReviews NF1: selected surveillance table6a/6b

    Parent inspected selected surveillance table6a/6b on17November2026; brain MRI clinically indicated, not all-body/current full-guideline appraisal.

  5. 5
    Shields et al2001: clinical variations in150 Coats cases; PMID11336930

    Selected indexed primary results inspected17November2026, not complete main text/figures or full abstract.

Original lecture link